The central insight behind MIMAC is that translation is an energetically demanding process, and cells receiving a large bolus of messenger RNA may lack the metabolic resources to exploit it fully. The researchers addressed this by co-packaging a second RNA that encodes a component of the mitochondrial NADH dehydrogenase complex, the enzyme that catalyzes the conversion of NADH to NAD+ while pumping protons to drive ATP synthesis. In the restructured nanoparticles, this metabolic RNA sits in the outer compartment and is released first, elevating intracellular ATP levels by up to 4.2-fold. Only afterward is the therapeutic RNA freed from the nanoparticle core, arriving in a cytosol already primed with the energy currency needed for efficient ribosomal activity and protein synthesis.

Creating such a hierarchical structure required more than simply mixing two RNAs with lipids. Conventional co-encapsulation and co-transfection strategies produce uncontrolled cargo distributions and, in the team’s experiments, failed to match the expression gains of the spatially organized particles. The MIMAC workflow instead runs preformed lipid nanoparticles through a chip containing arrays of microscale obstacles, whose geometry the authors optimized using COMSOL Multiphysics simulations of fluid mixing. Triangular obstacles with carefully tuned characteristic lengths and spacing generated the chaotic mixing needed to merge an mRNA-containing stream with the preformed particles under controlled pH and temperature conditions, with optimal insertion of the metabolic RNA occurring at pH 4.5 and 75 degrees Celsius, temperatures consistent with the phase transition range of the lipid formulation measured by differential scanning calorimetry.

Careful characterization confirmed that the process does not damage the cargo. Preformed nanoparticles carrying Spike mRNA passed through the chip without aggregation or leakage, and the integrity of the therapeutic RNA was preserved across the obstacle array. Fluorescent labeling of lipids and RNAs allowed the researchers to document the stratified internal organization directly, and accelerated release assays in serum-like media showed the expected temporal program: in the optimized ND/Spike configuration, the Spike mRNA was released early, followed by the metabolic ND mRNA, while reversing the loading order reversed the release sequence. Short-term storage at room temperature and at minus 20 degrees Celsius preserved the stratified structure, indicating practical stability for handling and distribution.

A notable strength of the platform is its modularity. The authors showed that MIMAC is compatible with multiple nucleic acid types, including linear RNA, circular RNA, self-amplifying RNA and plasmid DNA, and with varied lipid formulations beyond the classical four-component mixture of ionizable lipid, DSPC, cholesterol and PEG-lipid used as a benchmark. Transfection experiments across multiple cell lines demonstrated that the structured nanoparticles maintained high delivery efficiency, above 95 percent, while outperforming co-encapsulation, co-transfection and even exogenous ATP supplementation strategies for boosting target protein expression. This suggests that the benefit arises not merely from supplying ATP but from the coordinated timing of metabolic priming and therapeutic RNA availability, a synergy that conventional formulations cannot reproduce.

The therapeutic implications were tested in vivo in two vaccine contexts. In a syngeneic mouse model of human papillomavirus-driven cancer, an MIMAC-optimized vaccine encoding HPV antigens suppressed tumor growth by 89.2 percent and increased survival, demonstrating that the enhanced antigen expression translates into stronger anti-tumor immunity. The platform was then applied to SARS-CoV-2 vaccines, where MIMAC processing of existing vaccine designs boosted antibody titers by 62.3-fold to 174.8-fold. Critically, this potency gain meant that the structured vaccines maintained protective efficacy at one-tenth of the standard dose, a reduction with potentially far-reaching consequences for vaccine supply chains, manufacturing costs and dose-sparing strategies during pandemics.

Route of administration mattered, the study found. Comparisons of intravenous and intramuscular delivery showed differences in antibody responses and inflammatory markers such as serum IL-6, and in vivo imaging revealed that intravenous injection led to predominant hepatic accumulation of the nanoparticles, whereas intramuscular delivery supported the intended immunization profile. These observations underscore that the performance of even an optimized nanoparticle depends on how it reaches the relevant immune and tissue compartments, and they provide practical guidance for how MIMAC-based vaccines should be deployed in preclinical and clinical settings.

Scalability, often the Achilles heel of sophisticated nanomedicine, was addressed directly. The team developed a benchtop device capable of producing 200 doses per hour, suggesting that the reorganization chemistry can be integrated into realistic manufacturing workflows rather than remaining a laboratory curiosity. The authors also designed the chip parameters to be tunable, showing in simulation how obstacle number, size and spacing govern mixing efficiency across different Reynolds numbers, and demonstrating that varying the ratio of metabolic to therapeutic mRNA systematically tunes nanoparticle size and expression output. Such controllability is essential for regulatory development, where reproducible, well-characterized manufacturing processes are prerequisites for clinical translation.

The work arrives amid intense interest in improving the intracellular biology of lipid nanoparticle delivery. Prior efforts have enhanced mRNA vaccines through optimized sequence design, adjuvanted ionizable lipids, combinatorial lipid libraries and ATP-based formulation strategies. What distinguishes MIMAC is its focus on the internal spatial organization of co-delivered cargoes and the release kinetics that follow from it, effectively treating the nanoparticle as a programmable device rather than a passive container. This framing draws on principles from synthetic gene circuits and controlled-release science, applying them at the scale of a single lipid particle.

Cautious interpretation remains warranted, as with any preclinical study. The tumor and immunogenicity data come from mouse models, the long-term safety of adding a mitochondrial enzyme-encoding RNA to every vaccine dose has yet to be assessed in humans, and the authors note patent applications related to the technology, which may shape its development path. Nevertheless, the magnitude of the reported effects, spanning cancer vaccine efficacy, dose-sparing coronavirus immunization and modular compatibility with diverse cargo chemistries, positions microfluidics-mediated spatial control as a promising general strategy for the next generation of mRNA therapeutics, one in which the architecture of the delivery vehicle is engineered as deliberately as the drug it carries.

Subject of Research: Microfluidic spatial control of mRNA lipid nanoparticle architecture to enhance translation and vaccine potency

Article Title: Microfluidics-mediated spatial control of mRNA lipid nanoparticles primes translation and enhances vaccine potency

Article References: Microfluidics-mediated spatial control of mRNA lipid nanoparticles primes translation and enhances vaccine potency. (n.d.). https://doi.org/10.1038/s41551-026-01796-3

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01796-3

Keywords: mRNA vaccines, lipid nanoparticles, microfluidics, MIMAC, ATP metabolic priming, SARS-CoV-2, HPV cancer vaccine, sequential release, drug delivery, nanotechnology, translation efficiency, self-amplifying RNA